Susan Kao
Hematology & Oncology · Berkeley, CANPI 1396823167
Payments from drug & device makers
Across 43 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$154
- AstraZeneca$72
- Gilead$49
- Johnson & Johnson$47
- Bristol Myers Squibb$46
- Pharmacyclics LLC, An Abbvie Company$41
- plus $426 from 17 others
What the payments were for
- Food & beverage$78494%
- Education$526%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $154 |
| AstraZeneca | 3 | $72 |
| Gilead(2 entities) | 3 | $49 |
| Johnson & Johnson | 4 | $47 |
| Bristol Myers Squibb | 2 | $46 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $41 |
| Pfizer | 3 | $40 |
| Sanofi | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| EUSA Pharma (US) LLC | 1 | $30 |
| Exelixis Inc. | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Tesaro, Inc. | 1 | $26 |
| Seagen Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| Bayer | 1 | $22 |
| Clovis Oncology, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Merck | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $13 |
How this compares
$836 in reported general payments places this provider in the 20th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 245 | $3,249,147 |
| PomalystPomalidomide | 59 | $1,442,340 |
| BrukinsaZanubrutinib | 91 | $1,186,543 |
| JakafiRuxolitinib Phosphate | 50 | $698,711 |
| TagrissoOsimertinib Mesylate | 37 | $629,008 |
| NinlaroIxazomib Citrate | 31 | $420,047 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $236,697 |
| ImbruvicaIbrutinib | 16 | $216,831 |
| IbrancePalbociclib | 13 | $200,964 |
| VenclextaVenetoclax | 38 | $98,506 |
| AlvaizEltrombopag Choline | 16 | $90,636 |
| CalquenceAcalabrutinib Maleate | 11 | $79,289 |
| OrgovyxRelugolix | 14 | $35,339 |
| NivestymFilgrastim-Aafi | 40 | $30,765 |
| GranixTbo-Filgrastim | 27 | $14,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $32 | $1,442,34059 claims |
| AstraZenecaTagrisso, Calquence | $72 | $708,29748 claims |
| PfizerIbrance, Nivestym | $40 | $231,72853 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $41 | $216,83116 claims |
| AbbVieVenclexta, Gengraf | $19 | $100,59357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Berkeley
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.